"We are particularly pleased to partner with another forward-thinking Pennsylvania corporation," says Dr. Stephen Fonash, founder and Chairman of NanoHorizons. "Arrow's experience in the biomedical industry is invaluable to our efforts to bring nanotechnology to market in unique products, critical to the continuing effort to improve medical care," adds Robert Burlinson, President and CEO of NanoHorizons, Inc.
“We are particularly pleased to partner with another forward-thinking Pennsylvania corporation”
About NanoHorizons, Inc.
NanoHorizons, Inc. was founded in 2002 with a business focus on nanotechnology applications in the drug discovery, microelectronics and health care industries. The company has licensed a comprehensive portfolio of nanotechnology Intellectual Property from the Pennsylvania State University.
The initial product offering, QuickMass(TM) matrix free laser desorption plates, addresses the need for more cost effective pharmaceutical research and increased drug discovery capacity. Additional commercial initiatives are being pursued to meet needs for fast, high-sensitivity respiration monitors as well as humidity and gas sensors. Further, a manufacturing process used to place high performance logic, sensors, displays, MEMS and optoelectronics on inexpensive or mechanically flexible substrates offers licensing opportunities.
For more information, visit www.nanohorizons.com
About Arrow International, Inc.
Arrow International, Inc. develops, manufactures and markets a broad range of clinically advanced, disposable catheters and related products for critical and cardiac care. The Company's products are used primarily by anesthesiologists, critical care specialists, surgeons, emergency and trauma physicians, cardiologists, interventional radiologists, electrophysiologists, and other health care providers. The Company's common stock trades on The Nasdaq Stock Market(R) under the symbol ARRO.
For more information, visit http://www.arrowintl.com

